{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:44:14Z","timestamp":1767134654897,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd002028","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T00:00:00Z","timestamp":1479168000000},"record-id":"31084"},{"DOI":"10.1002\/14651858.cd002028","type":"withdrawal","label":"Withdrawal","source":"publisher","updated":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T00:00:00Z","timestamp":1479168000000}}],"reference-count":14,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002028.pub2","type":"journal-article","created":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T14:55:52Z","timestamp":1479308152000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oxcarbazepine add-on for drug-resistant partial epilepsy"],"prefix":"10.1002","volume":"2016","author":[{"given":"Sergio M","family":"Castillo","sequence":"first","affiliation":[{"name":"Hospital del Salvador; Servicio de Neurologia; Salvador 364 Providencia Santiago Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter B","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Epilepsy Research Group; Goesthe Strasse 5 D-14163 Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"White","sequence":"additional","affiliation":[{"name":"St Georges, University of London; Research Resource Unit, Department of Mental Health; Crammer Terrace Tooting London UK SW17 0RE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arif","family":"Shukralla","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Clinical Sciences Centre for Research and Education, Lower Lane Fazakerley Liverpool UK L9 7LJ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,11,15]]},"reference":[{"key":"10.1002\/14651858.CD002028.pub2-BIB1|cit1","unstructured":"Glauser T Nigro M Sachdeo R Bibas Bonet H Adjunctive therapy with oxcarbazepine in children with partial seizures 4295759"},{"key":"10.1002\/14651858.CD002028.pub2-BIB2|cit2","unstructured":"Halasz P Walker EB Elger CE Scaramelli A Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy 4295761"},{"issue":"6","key":"10.1002\/14651858.CD002028.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1528-1157.1987.tb03702.x","article-title":"Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine?","volume":"28","author":"Houtkooper","year":"1987","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD002028.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1212\/01.wnl.0000186800.18456.72","article-title":"Oxcarbazepine adjunctive therapy in infants and young children with partial seizures","volume":"65","author":"Pina-Garza","year":"2005","journal-title":"Neurology"},{"issue":"11","key":"10.1002\/14651858.CD002028.pub2-BIB5|cit5","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD012433","article-title":"Oxcarbazepine add-on for drug-resistant partial epilepsy","author":"Atim-Oluk","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD002028.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1528-1157.1998.tb01295.x","article-title":"Neuropsychological outcomes in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards","volume":"39","author":"Cochrane","year":"1998","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD002028.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Proposal for revised classification of epilepsies and epileptic syndromes","volume":"30","year":"1989","journal-title":"Epilepsia"},{"issue":"6","key":"10.1002\/14651858.CD002028.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2165\/00003495-199243060-00007","article-title":"Oxcarbazepine: a review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders","volume":"43","author":"Grant","year":"1992","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD002028.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/bmj.317.7167.1185","article-title":"The unpredictability paradox : review of empirical comparisons of randomised and non-randomised clinical trials","volume":"317","author":"Kunz","year":"1998","journal-title":"British Medical Journal"},{"issue":"8","key":"10.1002\/14651858.CD002028.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1528-1157.1997.tb01251.x","article-title":"The new antiepileptic drugs : a systematic review of their efficacy and tolerability","volume":"38","author":"Marson","year":"1997","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD002028.pub2-BIB11|cit11","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-3242-6","volume-title":"Generalized linear models","author":"McCullagh","year":"1989"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD002028.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1111\/j.1528-1157.1999.tb00919.x","article-title":"Evidence-based medicine and antiepileptic drugs","volume":"40","author":"Privitera","year":"1999","journal-title":"Epilepsia"},{"issue":"5","key":"10.1002\/14651858.CD002028.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD002028.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1212\/WNL.49.2.333","article-title":"Difficulties in extrapolating from clinical trial data to clinical practice : the case of antiepileptic drugs","volume":"49","author":"Walker","year":"1997","journal-title":"Journal of Neurology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD002028.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T06:03:50Z","timestamp":1702965830000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002028.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,11,15]]},"references-count":14,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002028.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,15]]}}}